OmniAb Unveils Groundbreaking High-Throughput Single B-cell Screening Platform xPloration at the 20th Annual PEGS Boston Summit’
EMERYVILLE, Calif. - OmniAb, Inc. (Nasdaq: OABI), a pioneer in the biopharmaceutical industry, captivated attendees at the 20th Annual PEGS Boston - The Essential Protein & Antibody Engineering Summit, with a presentation of its sophisticated high-throughput single B-cell screening platform, xPloration. This year’s summit, hosted at the Omni Hotel, provided a robust venue for OmniAb to showcase their innovation in antibody discovery and development.
Revolutionizing Antibody Discovery with xPloration’
OmniAb’s xPloration platform represents a monumental advancement in antibody discovery, harnessing the converging powers of high-throughput screening, machine learning, and Artificial Intelligence (AI). In a presentation en
Comments